Allosteric p38 kinase inhibitors

被引：2

作者：

Norman, Peter ^{[1
]}

机构：

[1] Norman Consulting, Burnham SL1 8JW, Bucks, England

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2006年 / 16卷 / 10期

关键词：

IL-1; MAPK; p38; rheumatoid arthritis; TNF-alpha;

D O I：

10.1517/13543776.16.10.1443

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Two applications claim N,N'-bisaryl urea derivatives as allosteric inhibitors of p38 MAPK and their use as anti-inflammatory agents. The compounds have been designed to stabilise a specific conformation of the kinase and to optimise selectivity by avoiding interactions with the ATP-binding domain of the kinase. They are the first application to describe the applicant's p38 inhibitor programme, which is close to investigational new drug filing.

引用

页码：1443 / 1448

页数：6

共 50 条

[41] Process Research and Development for Heterocyclic p38 MAP Kinase Inhibitors
Thiel, Oliver R.
Achmatowicz, Michal
Milburn, Robert M.
[J]. SYNLETT, 2012, (11) : 1564 - 1574
[42] p38 MAP kinase inhibitors: Many are made, but few are chosen
Dominguez, C
Powers, DA
Tamayo, N
[J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (04) : 421 - 430
[43] Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR
Angell, Richard M.
Angell, Tony D.
Bamborough, Paul
Brown, David
Brown, Murray
Buckton, Jacky B.
Cockerill, Stuart G.
Edwards, Chris D.
Jones, Katherine L.
Longstaff, Tim
Smee, Penny A.
Smith, Kathryn J.
Somers, Don O.
Walker, Ann L.
Willson, Malcolm
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (01) : 324 - 328
[44] SYNTHESIS OF HETEROARYL-FUSED PYRAZOLES AS P38 KINASE INHIBITORS
Abbot, Sarah C.
Billedeau, Roland J.
Dewdney, Nolan J.
Gabriel, Tobias
Goldstein, David M.
McCaleb, Kristen L.
Soth, Michael
Trejo-Martin, Teresa Alejandra
Zecic, Hasim
[J]. HETEROCYCLES, 2009, 78 (11) : 2811 - 2826
[45] 'Reverse' α-ketoamide-based p38 MAP kinase inhibitors
Montalban, Antonio Garrido
Boman, Erik
Chang, Chau-Dung
Ceide, Susana Conde
Dahl, Russell
Dalesandro, David
Delaet, Nancy G. J.
Erb, Eric
Gibbs, Andrew
Kahl, Jeff
Kessler, Linda
Lundstroem, Jan
Miller, Stephen
Nakanishi, Hiroshi
Roberts, Ed
Saiah, Eddine
Sullivan, Robert
Wang, Zhijun
Larson, Christopher J.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5456 - 5459
[46] Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase
Hammach, Abdelhakim
Barbosa, Antonio
Gaenzler, Faith Corbo
Fadra, Tazmeen
Goldberg, Daniel
Hao, Ming-Hong
Kroe, Rachel R.
Liu, Pingrong
Qian, Kevin C.
Ralph, Mark
Sarko, Christopher
Soleymanzadeh, Fariba
Moss, Nell
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) : 6316 - 6320
[47] Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase
Tamayo, N
Liao, L
Goldberg, M
Powers, D
Tudor, YY
Yu, V
Wong, LM
Henkle, B
Middleton, S
Syed, R
Harvey, T
Jang, G
Hungate, R
Dominguez, C
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) : 2409 - 2413
[48] The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
Wilson, KP
McCaffrey, PG
Hsiao, K
Pazhanisamy, S
Galullo, V
Bemis, GW
Fitzgibbon, MJ
Garon, PR
Murcko, MA
Su, MSS
[J]. CHEMISTRY & BIOLOGY, 1997, 4 (06): : 423 - 431
[49] Critical review of p38 MAP kinase inhibitors: a bioanalytical perspective
Wong, Philip
Hsieh, Faye
Roger Pham
James, Christopher A.
[J]. BIOANALYSIS, 2012, 4 (01) : 89 - 93
[50] Pharmacological characterization of pyrazolyl urea p38 kinase inhibitors.
Ranges, GE
Bortolon, E
Chau, T
Dixon, BR
Bhargava, A
Dumas, J
Gianpaolo-Ostravage, C
Hatoum-Mokdad, H
Housley, TJ
Shrikhande, A
Scott, WJ
Sibley, R
Wakefield, J
Wilhelm, SM
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U562 - U563

← 1 2 3 4 5 →